Table 4.
Associations of fibroblast growth factor 23 with incident CKD in sensitivity analyses
| Analyses | Per 1 SD Increase of ln FGF23 | ||
|---|---|---|---|
| Hazard Ratio | 95% Confidence Interval | P value | |
| 1. Main analysis of all participants (Table 3) | 1.09 | 0.94 to 1.27 | 0.25 |
| 2. Adjusted for prerandomization MDRD eGFR instead of month 4 MDRD eGFR | 1.07 | 0.92 to 1.24 | 0.38 |
| 3. Adjusted for prerandomization MDRD eGFR in addition to month 4 MDRD eGFR | 1.07 | 0.92 to 1.25 | 0.38 |
| 4. Adjusted for month 4 CKD-EPI eGFR instead of month 4 MDRD eGFR | 1.10 | 0.95 to 1.27 | 0.21 |
| 5. Adjusted for prerandomization CKD-EPI eGFR and month 4 CKD EPI eGFR | 1.08 | 0.93 to 1.25 | 0.33 |
| 6. Adjusted for baseline urine albumin-to-creatinine ratio | 1.09 | 0.93 to 1.26 | 0.29 |
| 7. Adjusted for history of any cardiovascular disease at baseline | 1.09 | 0.94 to 1.27 | 0.25 |
| 8. Adjusted for randomized BP intervention | 1.12 | 0.95 to 1.31 | 0.18 |
Main analysis results are from the fully adjusted models that included the following covariates:
age, sex, race, ethnicity, month 4 eGFR, BP, smoking, diabetes duration, hemoglobin A1C, body mass index, use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, glycemic control arm, and level of serum phosphate. MDRD, Modification of Diet in Renal Disease; CKD-EPI, CKD Epidemiology Collaboration; ln, natural log; FGF23, fibroblast growth factor 23.